Does the media refer more to ODTX or PLX?

In the previous week, Odyssey Therapeutics had 7 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 8 mentions for Odyssey Therapeutics and 1 mentions for Protalix BioTherapeutics. Odyssey Therapeutics' average media sentiment score of 0.52 beat Protalix BioTherapeutics' score of 0.00 indicating that Odyssey Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Odyssey Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RIGL or PLX?

In the previous week, Rigel Pharmaceuticals had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 2 mentions for Rigel Pharmaceuticals and 1 mentions for Protalix BioTherapeutics. Rigel Pharmaceuticals' average media sentiment score of 0.89 beat Protalix BioTherapeutics' score of 0.00 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to JBIO or PLX?

In the previous week, Jade Biosciences had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 2 mentions for Jade Biosciences and 1 mentions for Protalix BioTherapeutics. Jade Biosciences' average media sentiment score of 0.61 beat Protalix BioTherapeutics' score of 0.00 indicating that Jade Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to GLUE or PLX?

In the previous week, Monte Rosa Therapeutics had 8 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 9 mentions for Monte Rosa Therapeutics and 1 mentions for Protalix BioTherapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.59 beat Protalix BioTherapeutics' score of 0.00 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SANA or PLX?

In the previous week, Sana Biotechnology had 2 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 3 mentions for Sana Biotechnology and 1 mentions for Protalix BioTherapeutics. Sana Biotechnology's average media sentiment score of 1.08 beat Protalix BioTherapeutics' score of 0.00 indicating that Sana Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Protalix BioTherapeutics (PLX) Competitors

$2.78 +0.08 (+2.96%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.78 +0.01 (+0.18%)

As of 10/9/2026 07:44 PM Eastern

Compare

PLX vs. ODTX, RIGL, JBIO, GLUE, and SANA

Should you buy Protalix BioTherapeutics stock or one of its competitors? Protalix BioTherapeutics's main competitors and comparable companies include Odyssey Therapeutics (ODTX), Rigel Pharmaceuticals (RIGL), Jade Biosciences (JBIO), Monte Rosa Therapeutics (GLUE), and Sana Biotechnology (SANA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Protalix BioTherapeutics compare to Odyssey Therapeutics?

Odyssey Therapeutics (NASDAQ:ODTX) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Odyssey Therapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Odyssey Therapeutics' return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Odyssey Therapeutics	N/A	N/A	N/A
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Odyssey Therapeutics presently has a consensus target price of $37.00, suggesting a potential upside of 94.74%. Protalix BioTherapeutics has a consensus target price of $12.00, suggesting a potential upside of 331.65%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Odyssey Therapeutics had 7 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 8 mentions for Odyssey Therapeutics and 1 mentions for Protalix BioTherapeutics. Odyssey Therapeutics' average media sentiment score of 0.52 beat Protalix BioTherapeutics' score of 0.00 indicating that Odyssey Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Odyssey Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

16.5% of Protalix BioTherapeutics shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Protalix BioTherapeutics has higher revenue and earnings than Odyssey Therapeutics. Odyssey Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A
Protalix BioTherapeutics	$80.62M	2.78	$8.31M	$0.23	12.09

Summary

Odyssey Therapeutics beats Protalix BioTherapeutics on 7 of the 13 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Rigel Pharmaceuticals?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Rigel Pharmaceuticals presently has a consensus target price of $59.00, suggesting a potential upside of 20.21%. Protalix BioTherapeutics has a consensus target price of $12.00, suggesting a potential upside of 331.65%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Rigel Pharmaceuticals had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 2 mentions for Rigel Pharmaceuticals and 1 mentions for Protalix BioTherapeutics. Rigel Pharmaceuticals' average media sentiment score of 0.89 beat Protalix BioTherapeutics' score of 0.00 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rigel Pharmaceuticals has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of -0.09, indicating that its stock price is 109% less volatile than the broader market.

Rigel Pharmaceuticals has higher revenue and earnings than Protalix BioTherapeutics. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	3.09	$367.02M	$16.32	3.01
Protalix BioTherapeutics	$80.62M	2.78	$8.31M	$0.23	12.09

Rigel Pharmaceuticals has a net margin of 116.30% compared to Protalix BioTherapeutics' net margin of -21.03%. Rigel Pharmaceuticals' return on equity of 22.95% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	116.30%	22.95%	17.19%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Rigel Pharmaceuticals beats Protalix BioTherapeutics on 14 of the 16 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, Jade Biosciences had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 2 mentions for Jade Biosciences and 1 mentions for Protalix BioTherapeutics. Jade Biosciences' average media sentiment score of 0.61 beat Protalix BioTherapeutics' score of 0.00 indicating that Jade Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Protalix BioTherapeutics has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A
Protalix BioTherapeutics	$80.62M	2.78	$8.31M	$0.23	12.09

Jade Biosciences has a beta of 1.64, suggesting that its share price is 64% more volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market.

Jade Biosciences presently has a consensus target price of $51.75, suggesting a potential upside of 259.62%. Protalix BioTherapeutics has a consensus target price of $12.00, suggesting a potential upside of 331.65%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Jade Biosciences has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-49.11%	-45.62%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 23.1% of Jade Biosciences shares are owned by insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Jade Biosciences and Protalix BioTherapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Protalix BioTherapeutics has a net margin of -21.03% compared to Monte Rosa Therapeutics' net margin of -560.85%. Protalix BioTherapeutics' return on equity of -30.89% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Protalix BioTherapeutics has lower revenue, but higher earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	7.11	-$38.63M	-$1.76	N/A
Protalix BioTherapeutics	$80.62M	2.78	$8.31M	$0.23	12.09

Monte Rosa Therapeutics presently has a consensus target price of $27.63, indicating a potential upside of 168.20%. Protalix BioTherapeutics has a consensus target price of $12.00, indicating a potential upside of 331.65%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Monte Rosa Therapeutics had 8 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 9 mentions for Monte Rosa Therapeutics and 1 mentions for Protalix BioTherapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.59 beat Protalix BioTherapeutics' score of 0.00 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Monte Rosa Therapeutics has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of -0.09, indicating that its share price is 109% less volatile than the broader market.

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Monte Rosa Therapeutics beats Protalix BioTherapeutics on 9 of the 17 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Protalix BioTherapeutics has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A
Protalix BioTherapeutics	$80.62M	2.78	$8.31M	$0.23	12.09

Sana Biotechnology has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

In the previous week, Sana Biotechnology had 2 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 3 mentions for Sana Biotechnology and 1 mentions for Protalix BioTherapeutics. Sana Biotechnology's average media sentiment score of 1.08 beat Protalix BioTherapeutics' score of 0.00 indicating that Sana Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sana Biotechnology has a beta of 2.18, meaning that its share price is 118% more volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of -0.09, meaning that its share price is 109% less volatile than the broader market.

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by company insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Sana Biotechnology presently has a consensus target price of $9.33, indicating a potential upside of 234.53%. Protalix BioTherapeutics has a consensus target price of $12.00, indicating a potential upside of 331.65%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Sana Biotechnology beats Protalix BioTherapeutics on 9 of the 16 factors compared between the two stocks.

Get Protalix BioTherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLX vs. The Competition

Export

Metric	Protalix BioTherapeutics	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$223.99M	$3.93B	$7.25B	$23.07B
Dividend Yield	N/A	3.64%	2.52%	3.72%
P/E Ratio	-21.38	13.55	275.01	28.58
Price / Sales	2.78	1,209.42	582.85	20.72
Price / Cash	17.80	119.49	76.96	38.93
Price / Book	5.91	17.17	11.22	4.72
Net Income	$8.31M	-$22.69M	$3.50B	$1.07B
7 Day Performance	2.58%	-1.34%	-0.89%	0.35%
1 Month Performance	5.30%	-8.04%	-4.02%	-3.40%
1 Year Performance	17.80%	14.18%	7.13%	9.40%

Protalix BioTherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLX Protalix BioTherapeutics	2.3641 of 5 stars	$2.78 +3.0%	$12.00 +331.7%	+17.8%	$223.99M	$80.62M	N/A	226
ODTX Odyssey Therapeutics	2.8952 of 5 stars	$18.13 -13.0%	$35.75 +97.2%	N/A	$871.31M	$99K	N/A	100	News Coverage Analyst Forecast
RIGL Rigel Pharmaceuticals	4.2957 of 5 stars	$46.11 -3.5%	$59.00 +28.0%	+74.2%	$853.13M	$276.79M	2.83	174	Analyst Upgrade
JBIO Jade Biosciences	1.8452 of 5 stars	$13.41 -4.7%	$51.75 +285.9%	+58.5%	$852.88M	N/A	N/A	55
GLUE Monte Rosa Therapeutics	2.3866 of 5 stars	$9.87 -3.9%	$27.63 +179.9%	+2.6%	$842.01M	$123.67M	N/A	173

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PLX) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protalix BioTherapeutics (PLX) Competitors

PLX vs. ODTX, RIGL, JBIO, GLUE, and SANA

How does Protalix BioTherapeutics compare to Odyssey Therapeutics?

Summary

How does Protalix BioTherapeutics compare to Rigel Pharmaceuticals?

Summary

How does Protalix BioTherapeutics compare to Jade Biosciences?

Summary

How does Protalix BioTherapeutics compare to Monte Rosa Therapeutics?

Summary

How does Protalix BioTherapeutics compare to Sana Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX vs. The Competition

Protalix BioTherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protalix BioTherapeutics (PLX) Competitors

PLX vs. ODTX, RIGL, JBIO, GLUE, and SANA

How does Protalix BioTherapeutics compare to Odyssey Therapeutics?

Is ODTX or PLX more profitable?

Do analysts recommend ODTX or PLX?

Does the media refer more to ODTX or PLX?

Do insiders & institutionals hold more shares of ODTX or PLX?

Which has higher earnings & valuation, ODTX or PLX?

Summary

How does Protalix BioTherapeutics compare to Rigel Pharmaceuticals?

Do analysts prefer RIGL or PLX?

Does the media prefer RIGL or PLX?

Which has more volatility and risk, RIGL or PLX?

Which has stronger valuation and earnings, RIGL or PLX?

Is RIGL or PLX more profitable?

Do insiders & institutionals hold more shares of RIGL or PLX?

Summary

How does Protalix BioTherapeutics compare to Jade Biosciences?

Does the media refer more to JBIO or PLX?

Which has preferable valuation & earnings, JBIO or PLX?

Which has more risk and volatility, JBIO or PLX?

Do analysts rate JBIO or PLX?

Is JBIO or PLX more profitable?

Do institutionals & insiders believe in JBIO or PLX?

Summary

How does Protalix BioTherapeutics compare to Monte Rosa Therapeutics?

Is GLUE or PLX more profitable?

Which has higher valuation & earnings, GLUE or PLX?

Do analysts prefer GLUE or PLX?

Does the media refer more to GLUE or PLX?

Which has more volatility & risk, GLUE or PLX?

Do institutionals and insiders have more ownership in GLUE or PLX?

Summary

How does Protalix BioTherapeutics compare to Sana Biotechnology?

Which has higher earnings and valuation, SANA or PLX?

Is SANA or PLX more profitable?

Does the media favor SANA or PLX?

Which has more risk & volatility, SANA or PLX?

Do institutionals and insiders believe in SANA or PLX?

Do analysts rate SANA or PLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX vs. The Competition

Protalix BioTherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools